organization · Reporting owner
Southpoint GP, LP
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| FENNEC PHARMACEUTICALS INC.FENC · Entity 5601 | 10% owner | December 24, 2025 | December 29, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
FENNEC PHARMACEUTICALS INC.
Report date December 24, 2025 · Filed December 29, 2025
Jointly reported with Southpoint Capital Advisors LP, Southpoint Capital Advisors LLC, Southpoint GP, LLC, Clark John Smith II
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 2,744,741 |
Reported balance
After 2025-12-24 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2025-12-24 · Sale · Disposed 1,000,000 · Balance 2,744,741 F1: The securities are directly held by Southpoint Master Fund, LP for which Southpoint Capital Advisors LP serves as the investment manager and Southpoint GP, LP serves as the general partner. Southpoint Capital Advisors LLC serves as the general partner of Southpoint Capital Advisors LP and Southpoint GP, LLC serves as the general partner of Southpoint GP, LP. John S. Clark II serves as managing member of both Southpoint Capital Advisors LLC and Southpoint GP, LLC. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The securities are directly held by Southpoint Master Fund, LP for which Southpoint Capital Advisors LP serves as the investment manager and Southpoint GP, LP serves as the general partner. Southpoint Capital Advisors LLC serves as the general partner of Southpoint Capital Advisors LP and Southpoint GP, LLC serves as the general partner of Southpoint GP, LP. John S. Clark II serves as managing member of both Southpoint Capital Advisors LLC and Southpoint GP, LLC. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or his pecuniary interest therein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 24, 2025 Filed Dec 29, 2025 21:34 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | SaleCommon Stock | 1,000,000 | $7.50 | $7,500,000.00 |
DisclosureSEC source: 0001012975-25-000985 · form4.xml · nonDerivative · entry 1 Southpoint Capital Advisors LP · CIK 0001319998 · 10% owner Southpoint Capital Advisors LLC · CIK 0001378377 · 10% owner Southpoint GP, LP · CIK 0001378376 · 10% owner Southpoint GP, LLC · CIK 0001378378 · 10% owner Clark John Smith II · CIK 0001378379 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 2,744,741 F1 · ownership.nature: The securities are directly held by Southpoint Master Fund, LP for which Southpoint Capital Advisors LP serves as the investment manager and Southpoint GP, LP serves as the general partner. Southpoint Capital Advisors LLC serves as the general partner of Southpoint Capital Advisors LP and Southpoint GP, LLC serves as the general partner of Southpoint GP, LP. John S. Clark II serves as managing member of both Southpoint Capital Advisors LLC and Southpoint GP, LLC. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or his pecuniary interest therein. Read SEC document |
| November 18, 2025 Filed Nov 20, 2025 21:07 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | SaleCommon Stock | 19,341 | $8.79 | $170,048.01 |
DisclosureSEC source: 0001012975-25-000806 · form4.xml · nonDerivative · entry 1 Southpoint Capital Advisors LP · CIK 0001319998 · 10% owner Southpoint Capital Advisors LLC · CIK 0001378377 · 10% owner Southpoint GP, LP · CIK 0001378376 · 10% owner Southpoint GP, LLC · CIK 0001378378 · 10% owner Clark John Smith II · CIK 0001378379 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 3,744,741 F2 · price: The transaction was executed in multiple trades at prices ranging from $8.75 to $8.845. The price above reflects the weighted average sales price. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer or a security holder of the Issuer. F1 · ownership.nature: The securities are directly held by Southpoint Master Fund, LP for which Southpoint Capital Advisors LP serves as the investment manager and Southpoint GP, LP serves as the general partner. Southpoint Capital Advisors LLC serves as the general partner of Southpoint Capital Advisors LP and Southpoint GP, LLC serves as the general partner of Southpoint GP, LP. John S. Clark II serves as managing member of both Southpoint Capital Advisors LLC and Southpoint GP, LLC. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or his pecuniary interest therein. Read SEC document |
| November 17, 2025 Filed Nov 18, 2025 01:42 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | SaleCommon Stock | 85,918 | $8.79 | $755,193.44 |
DisclosureSEC source: 0001012975-25-000793 · form4.xml · nonDerivative · entry 2 Southpoint Capital Advisors LP · CIK 0001319998 · 10% owner Southpoint Capital Advisors LLC · CIK 0001378377 · 10% owner Southpoint GP, LP · CIK 0001378376 · 10% owner Southpoint GP, LLC · CIK 0001378378 · 10% owner Clark John Smith II · CIK 0001378379 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 3,764,082 F3 · price: The transaction was executed in multiple trades at prices ranging from $8.75 to $8.97. The price above reflects the weighted average sales price. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer or a security holder of the Issuer. F1 · ownership.nature: The securities are directly held by Southpoint Master Fund, LP for which Southpoint Capital Advisors LP serves as the investment manager and Southpoint GP, LP serves as the general partner. Southpoint Capital Advisors LLC serves as the general partner of Southpoint Capital Advisors LP and Southpoint GP, LLC serves as the general partner of Southpoint GP, LP. John S. Clark II serves as managing member of both Southpoint Capital Advisors LLC and Southpoint GP, LLC. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or his pecuniary interest therein. Read SEC document |
| November 14, 2025 Filed Nov 18, 2025 01:42 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | SaleCommon Stock | 160,100 | $8.00 | $1,280,431.77 |
DisclosureSEC source: 0001012975-25-000793 · form4.xml · nonDerivative · entry 1 Southpoint Capital Advisors LP · CIK 0001319998 · 10% owner Southpoint Capital Advisors LLC · CIK 0001378377 · 10% owner Southpoint GP, LP · CIK 0001378376 · 10% owner Southpoint GP, LLC · CIK 0001378378 · 10% owner Clark John Smith II · CIK 0001378379 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 3,850,000 F2 · price: The transaction was executed in multiple trades at prices ranging from $7.86 to $8.15. The price above reflects the weighted average sales price. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer or a security holder of the Issuer. F1 · ownership.nature: The securities are directly held by Southpoint Master Fund, LP for which Southpoint Capital Advisors LP serves as the investment manager and Southpoint GP, LP serves as the general partner. Southpoint Capital Advisors LLC serves as the general partner of Southpoint Capital Advisors LP and Southpoint GP, LLC serves as the general partner of Southpoint GP, LP. John S. Clark II serves as managing member of both Southpoint Capital Advisors LLC and Southpoint GP, LLC. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or his pecuniary interest therein. Read SEC document |
| October 09, 2025 Filed Oct 9, 2025 21:31 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | SaleCommon Stock | 20,609 | $9.35 | $192,613.77 |
DisclosureSEC source: 0001012975-25-000621 · form4.xml · nonDerivative · entry 3 Southpoint Capital Advisors LP · CIK 0001319998 · 10% owner Southpoint Capital Advisors LLC · CIK 0001378377 · 10% owner Southpoint GP, LP · CIK 0001378376 · 10% owner Southpoint GP, LLC · CIK 0001378378 · 10% owner Clark John Smith II · CIK 0001378379 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 4,010,100 F4 · price: The transaction was executed in multiple trades at prices ranging from $9.30 to $9.42. The price above reflects the weighted average sales price. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer or a security holder of the Issuer. F1 · ownership.nature: The securities are directly held by Southpoint Master Fund, LP for which Southpoint Capital Advisors LP serves as the investment manager and Southpoint GP, LP serves as the general partner. Southpoint Capital Advisors LLC serves as the general partner of Southpoint Capital Advisors LP and Southpoint GP, LLC serves as the general partner of Southpoint GP, LP. John S. Clark II serves as managing member of both Southpoint Capital Advisors LLC and Southpoint GP, LLC. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or his pecuniary interest therein. Read SEC document |
| October 08, 2025 Filed Oct 9, 2025 21:31 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | SaleCommon Stock | 19,605 | $9.47 | $185,722.09 |
DisclosureSEC source: 0001012975-25-000621 · form4.xml · nonDerivative · entry 2 Southpoint Capital Advisors LP · CIK 0001319998 · 10% owner Southpoint Capital Advisors LLC · CIK 0001378377 · 10% owner Southpoint GP, LP · CIK 0001378376 · 10% owner Southpoint GP, LLC · CIK 0001378378 · 10% owner Clark John Smith II · CIK 0001378379 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 4,030,709 F3 · price: The transaction was executed in multiple trades at prices ranging from $9.31 to $9.61. The price above reflects the weighted average sales price. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer or a security holder of the Issuer. F1 · ownership.nature: The securities are directly held by Southpoint Master Fund, LP for which Southpoint Capital Advisors LP serves as the investment manager and Southpoint GP, LP serves as the general partner. Southpoint Capital Advisors LLC serves as the general partner of Southpoint Capital Advisors LP and Southpoint GP, LLC serves as the general partner of Southpoint GP, LP. John S. Clark II serves as managing member of both Southpoint Capital Advisors LLC and Southpoint GP, LLC. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or his pecuniary interest therein. Read SEC document |
| October 07, 2025 Filed Oct 9, 2025 21:31 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | SaleCommon Stock | 26,900 | $9.59 | $257,892.99 |
DisclosureSEC source: 0001012975-25-000621 · form4.xml · nonDerivative · entry 1 Southpoint Capital Advisors LP · CIK 0001319998 · 10% owner Southpoint Capital Advisors LLC · CIK 0001378377 · 10% owner Southpoint GP, LP · CIK 0001378376 · 10% owner Southpoint GP, LLC · CIK 0001378378 · 10% owner Clark John Smith II · CIK 0001378379 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 4,050,314 F2 · price: The transaction was executed in multiple trades at prices ranging from $9.47 to $9.70. The price above reflects the weighted average sales price. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer or a security holder of the Issuer. F1 · ownership.nature: The securities are directly held by Southpoint Master Fund, LP for which Southpoint Capital Advisors LP serves as the investment manager and Southpoint GP, LP serves as the general partner. Southpoint Capital Advisors LLC serves as the general partner of Southpoint Capital Advisors LP and Southpoint GP, LLC serves as the general partner of Southpoint GP, LP. John S. Clark II serves as managing member of both Southpoint Capital Advisors LLC and Southpoint GP, LLC. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or his pecuniary interest therein. Read SEC document |
| May 04, 2020 Filed May 6, 2020 20:05 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | PurchaseCommon Stock | 80,000 | $6.25 | $500,000.00 |
DisclosureSEC source: 0001012975-20-000407 · edgar.xml · nonDerivative · entry 1 Southpoint Capital Advisors LP · CIK 0001319998 · 10% owner Southpoint Capital Advisors LLC · CIK 0001378377 · 10% owner Southpoint GP, LP · CIK 0001378376 · 10% owner Southpoint GP, LLC · CIK 0001378378 · 10% owner Clark John Smith II · CIK 0001378379 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 4,077,214 F1 · ownership.nature: The securities are directly held by Southpoint Master Fund, LP for which Southpoint Capital Advisors LP serves as the investment manager and Southpoint GP, LP serves as the general partner. Southpoint Capital Advisors LLC serves as the general partner of Southpoint Capital Advisors LP and Southpoint GP, LLC serves as the general partner of Southpoint GP, LP. John S. Clark II serves as managing member of both Southpoint Capital Advisors LLC and Southpoint GP, LLC. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or his pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.